This poster presents the results from the efforts of an immunogenicity assay developed for a drug compound, showing required improvement in drug tolerance due to high levels of the drug in clinical trial subjects. 

Q² Solutions services can meet your immunogenicity and immunoassay needs from method development and validation, through sample analysis and customized reporting. Our scientists have extensive experience developing and validating variety of assays that support drug development including ELISA, Electrochemiluminescence (ECL), and cell-based immunoassays. Learn more about how we can help you build the right assay to get the data you need.

Authors: Shoshana Oberstein, Michelle Lang, and Paul Rhyne

Complete the form below to access this scientific poster